60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With Three Planned Trial Sites For Tafenoquine Babesiosis Study
$SXTP
Biotechnology: Pharmaceutical Preparations
Health Care
- The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center
- Patient enrollment has begun; interim results anticipated by September, 2025
- In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tick-borne, potentially life-threatening illness
- Case studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior treatment has failed
- Total cumulative accessible market through the end of patent protection in the U.S. for ARAKODA® (tafenoquine) for babesiosis is approximately 400,000 patients